$1.32
0.00% day before yesterday
Nasdaq, Jan 02, 10:04 pm CET
ISIN
US3741631036
Symbol
GERN

Geron Corporation Stock price

$1.32
+0.09 7.32% 1M
-0.08 5.71% 6M
+0.00 0.00% YTD
-2.28 63.33% 1Y
-1.10 45.45% 3Y
-0.31 19.02% 5Y
-3.26 71.18% 10Y
-6.81 83.77% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.00 0.00%
ISIN
US3741631036
Symbol
GERN
Industry

Key metrics

Basic
Market capitalization
$842.6m
Enterprise Value
$710.7m
Net debt
positive
Cash
$380.5m
Shares outstanding
638.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.6 | 4.4
EV/Sales
3.9 | 3.7
EV/FCF
negative
P/B
3.4
Financial Health
Equity Ratio
47.2%
Return on Equity
-62.3%
ROCE
-13.6%
ROIC
-
Debt/Equity
1.0
Financials (TTM | estimate)
Revenue
$183.4m | $190.5m
EBITDA
$-64.5m | $-72.2m
EBIT
$-65.0m | $-65.9m
Net Income
$-79.6m | $-73.8m
Free Cash Flow
$-132.9m
Growth (TTM | estimate)
Revenue
522.1% | 147.4%
EBITDA
68.8% | 58.3%
EBIT
68.6% | 62.1%
Net Income
60.3% | 57.7%
Free Cash Flow
38.7%
Margin (TTM | estimate)
Gross
97.7%
EBITDA
-35.2% | -37.9%
EBIT
-35.5%
Net
-43.4% | -38.7%
Free Cash Flow
-72.5%
More
EPS
$-0.1
FCF per Share
$-0.2
Short interest
12.5%
Employees
229
Rev per Employee
$340.0k
Show more

Is Geron Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Geron Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Geron Corporation forecast:

9x Buy
69%
3x Hold
23%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Geron Corporation forecast:

Buy
69%
Hold
23%
Sell
8%

Financial data from Geron Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
183 183
522% 522%
100%
- Direct Costs 4.22 4.22
779% 779%
2%
179 179
525% 525%
98%
- Selling and Administrative Expenses 161 161
30% 30%
88%
- Research and Development Expense 81 81
28% 28%
44%
-65 -65
69% 69%
-35%
- Depreciation and Amortization 0.54 0.54
6% 6%
0%
EBIT (Operating Income) EBIT -65 -65
69% 69%
-35%
Net Profit -80 -80
60% 60%
-43%

In millions USD.

Don't miss a Thing! We will send you all news about Geron Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Geron Corporation Stock News

Neutral
GlobeNewsWire
16 days ago
FOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted stock options to purchase an aggregate of 320,000 shares of common stock to one newly hired employee as an inducement material to such employee's acceptance of employment with Geron.
Neutral
GlobeNewsWire
23 days ago
Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced a strategic restructuring plan inten...
Neutral
GlobeNewsWire
26 days ago
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in lower-risk MDS
More Geron Corporation News

Company Profile

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Head office United States
CEO Dawn Bir
Employees 229
Founded 1990
Website www.geron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today